arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Cabaletta Bio, Inc.

CABA
$1.26 ▼ -0.16 (-11.27%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
9 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cabaletta Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -121.4% ↘
FCF / Share None
Trailing P/E —
Price / Book 1.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-167.86M
↓ -44.9% —
FCF / Share Free cash flow per share
$-46.43
↓ -465.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
5
Financial Health ↑
14
Cash Quality →
53

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 35 quarters